在格雷夫斯眼病中IGF-1R抑制剂的进展
1Department of Ophthalmology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
International ophthalmology
|November 22, 2024
概括
格雷夫斯眼科病的治疗面临着葡萄糖皮质类药物的挑战. 一种IGF-1R抑制剂Teprotumumab在降低甲状腺亡和改变与甲状腺相关的眼科病变中的疾病进展方面表现有前途.
科学领域:
- 内分泌学和免疫学.
- 眼科医生 眼科 眼科
背景情况:
- 格雷夫斯眼病 (Graves' ophthalmopathy,GO) 是格雷夫斯病的一个常见表现,通常用葡萄糖皮质类药物治疗.
- 目前对GO的治疗有局限性,包括副作用,复发和无法改变疾病进展.
- 胰岛素样生长因子-I受体 (IGF-1R) 信号通路与GO和其他免疫相关疾病的发病有关.
研究的目的:
- 审查IGF-1R在Graves眼病中的作用.
- 讨论IGF-1R抑制剂的治疗潜力,如teprotumumab,用于甲状腺相关的眼科病.
主要方法:
- 关于格雷夫斯眼病,IGF-1R信号传递和teprotumumab临床试验的现有文献的综述.
- 在GO的背景下分析IGF-1R抑制剂的作用机制.
主要成果:
- 针对IGF-1R的一种单克隆抗体Teprotumumab在临床试验中与安慰剂相比,在降低proptosis方面表现出有效性.
- 在停止葡萄糖皮质类药物治疗后出现疾病恶化的患者中,teprotumumab可能会带来好处.
结论:
- IGF-1R抑制剂代表了对格雷夫斯眼病的有前途的治疗策略.
- 向IGF-1R可能提供一种新的方法来控制疾病的进展,并改善甲状腺相关眼科病的结果.
相关概念视频
Open Angle Glaucoma: Treatment
393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
393
Angle Closure Glaucoma: Treatment
437
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
437
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Glaucoma: Overview
508
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
508


